glp-1-based treatments approved for weight loss 2025 Weight-loss drugs such as Ozempic were in the headlines a lot in – and patent protections these drugs expire in some countries in 2026. In this edition of #PeriodicGraphics in @ Blockbuster GLP-1 Diabetes and Weight

We partner with NPR stations across the Midwest and surrounding areas including KBIA and KCUR in Missouri, Iowa Public Radio, Ideastream in Ohio and WFPL in Kentucky

The United States is the world's dominant GLP-1 receptor agonist market by an enormous margin, with over 45% of global GLP-1 revenues generated domestically despite representing less than 5% of the world's diabetes and obesity patient population

[173] In the STEP-HFpEF trial including people with obesity and heart failure with preserved ejection fraction, weight loss was associated with improvements in heart failure symptoms and functional capacity

Pearls and Quotes Clinical Implementation of GLP-1 Receptor Agonists GLP-1 agonists work through a variety of mechanisms to counteract metabolic disease

With both GLP-1s and psychedelics becoming increasingly popular, it will be interesting to see what else is uncovered

Review Article Other versions: (Verbatim name) ID (Catalog Number) Invalid DOI was provided, please try again ContentsContents Article InfoArticle Info CiteCite MetricsMetrics CommentComment RelatedRelated FigsFigs TabsTabs RefsRefs CitedCited Article title Abstract Keywords Introduction Pharmacogenetics in type 2 diabetes What is glucagon-like peptide-1 (GLP-1) and their role in the glucose metabolism